Kornimate/medical-research-clean huggingface dataset:
treatment protocol to monitor the safety of a 200 mg dose of bicalutamide in patients with advanced prostate cancer

Conditions: Prostate Cancer

Summary: this is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of casodex. patient will receive casodex as long as physician feels that he is benefiting from this form of therapy.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the prostate gland * patients with advanced prostate cancer * adult male over the age of 18 years old * normal liver function (ast \< 2 x upper limit normal) exclusion criteria: * ecog performance status of 4. * previous history or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years.

Keywords: safety
efficacy of a gluten-free diet in difficult to manage nephrotic syndrome: utility of plasma zonulin levels as a predictive biomarker

Conditions: Nephrotic Syndrome

Summary: elevated plasma zonulin levels, which are supportive of a diagnosis of cd (celiac disease) in children with gastrointestinal symptoms, may indicate patients with difficult-to-manage ns who will benefit from initiation of a gfd (gluten free diet). this pilot study will determine whether high plasma zonulin levels can be used as a screening tool to identify patients with ns (nephrotic syndrome) who are likely to demonstrate a beneficial response to a gfd. it will provide important information about the feasibility of testing the efficacy of a gfd for this condition and assist in the design and sample size calculation for a definitive trial to test the beneficial effect of this dietary intervention. although ns is a rare condition in childhood, it is a chronic disease that can lead to short- and long-term disability especially in those with difficult-to-manage disease. there is an urgent need to develop safe and effective new therapies in this subgroup. this project may indicate the utility of a common dietary modification, a gfd, to treat these patients. the growing medical use of and greater access to gluten-free food items underscore the feasibility and timeliness of this approach.


Eligibility criteria:
inclusion criteria: * steroid sensitive ns: complete remission of proteinuria in response to administration of a standard course of corticosteroids * difficult-to-manage ns: disease that cannot be controlled without incurring intolerable side effects from currently available immunosuppressive agents, namely corticosteroids, calcineurin inhibitors, mycophenolate mofetil, or rituximab. patients with biopsy-proven mcd or fsgs will be eligible as long as they have steroid sensitive disease. however, a renal biopsy will not be required for enrollment into the trial. exclusion criteria: * any patient diagnosed with nephrotic syndrome that is not considered steroid sensitive or frequently relapsing * pre-existing celiac disease or gastro-intestinal disorder that precludes use of a gfd
the effect of aroma on fatigue scores among women with hypothyroidism

Conditions: Fatigue; Hypothyroidism

Summary: this study evaluates the effects of an inhaled blend of essential oils on fatigue scores among women who have hypothyroidism. half of the participants will receive an essential oil blend to inhale daily for two weeks while the other half will serve as controls and inhale a carrier oil.

the inhalation of certain essential oils has been found to increase stamina and reduce fatigue among athletes but have not been evaluated for the purpose of reducing fatigue among women who experience fatigue as a result of a hypothyroid condition. the essential oils used in this study are inhaled mid-afternoon, the time in which women with hypothyroidism typically experience the lowest levels of energy during the day, otherwise known as the "afternoon slump." the essential oil is administered during this time to evaluate both the immediate effects on fatigue as well as the overall effects, with measurements at the end of both the first and second week of the study. fatigue is measured on a multi-dimensional scale, a validated instrument that measures not only physical fatigue but also emotional and mental fatigue.

Eligibility criteria:
inclusion criteria: * female * diagnosed with hypothyroidism * otherwise healthy exclusion criteria: • history of thyroid cancer

Keywords: aromatherapy fatigue hypothyroidism essential oils
maintenance therapy of apatinib after chemoradiotherapy in metastatic nasopharyngeal carcinoma

Conditions: Nasopharyngeal Neoplasms

Summary: the study is to evaluate the efficacy and safety of apatinib as maintenace therapy for nasopharyngeal carcinoma with metastasis after chemoradiotherapy, including progress free survival(pfs)、overall survival (os)、quality of life score (qol) and evaluation of drug safety.

in locally advanced nasopharyngeal carcinoma(npc), although radiotherapy and chemotherapy has been given, patients still locally recurrence and distant metastasis. there is no standard treatment recommendation for metastatic npc who failed to chemoradiotherapy therapy. apatinib has been approved as a second-line treatment for advanced gastric cancer. several phase iii studies of liver cancer, non small cell lung cancer and other tumors also showed apatinib has less toxicities and better tolerance. however, the clinical application of apatinib in nasopharyngeal carcinoma is still lack of evidence-based medicine. and this trial is designed to investigate the efficacy and safety of apatinib as maintenance therapy after chemoradiotherapy in nasopharyngeal carcinoma with metastasis.

Eligibility criteria:
inclusion criteria: * male and female patients aged ranging from 18 to 75 years old. * naive or recurrent nasopharyngeal carcinoma with metastasis after chemotherapy or radiotherapy. * eastern cooperative oncology group (ecog) performance status of 0 - 2. * adequate hematologic (neutrophil count\>=1.5×109/l, hemoglobin\>=80g/l, platelets\>=80×109/l), hepatic function (aspartate transaminase (ast) \& alanine transaminase(alt) =\<upper normal limit(unl) x2, bilirubin level =\< unl x 1.5). * adequate renal function (creatinine clearance ≥ 60 ml/min). * patients have the ability to understand and voluntarily sign the informed consent, and allow adequate follow-up. exclusion criteria: * previously, patients did receive the therapy of apatinib or other vegfr inhibitor, such as sorafenib, sunitinib. * difficulties in taking pills (inability to swallow tablets,gi tract resection, chronic bacillary diarrhea and intestinal obstruction). * bleeding tendency or coagulation disorders. * with brain metastases. * uncontrolled hypertension (systolic pressure\>150 mmhg , or diastolic pressure\> 90 mmhg). * urine protein≥++, or urine protein in 24 hours≥1.0g * severe uncured wounds, ulcers or fracture. * pregnant or breast-feeding. * patients with epilepsy who need to take medicine (such as steroids or anti epilepsy agents). * patients have these symptoms, such as neurological diseases, mental illness, serious infection. * the researcher believe that the patient is not suitable to participate in the study.
evaluation of salivary galectin-8, galectin-9 and rankl levels of individuals with different periodontal diseases

Conditions: Periodontal Diseases

Summary: the aim of this study is; detection of galectin-8, galectin-9 and rankl levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. materials and methods: samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (p, n=20), gingivitis(g, n=20) and healthy periodontium (s, n=20). full-mouth clinical periodontal measurements including probing depth (pd), clinical attachment level (cal), bleeding on probing (bop), gingival index (gi) and plaque index (pi) were also recorded. enzyme-linked immunosorbent assay (elisa) was used to determine galectin-8, galectin-9 and rankl levels in the biological samples.


Eligibility criteria:
inclusion criteria: * systemically healthy (the determination of healthy volunteers will be based on the statements of the patients in the anamnesis. no additional examinations will be made.) * at least twenty permanent teeth in the mouth * non-smoker * no medication for continuous use * those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months. * not in pregnancy or lactation period. * for the periodontitis group that has not received periodontal treatment in the last 6 months * for the periodontitis group; according to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss * for the gingivitis group; according to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss * for healthy group; according to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study. exclusion criteria: * any oral or systemic disease * regularly using a systemic medication * during pregnancy or lactation * received periodontal treatment within the last 6 months. * those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months * smokers are not included in the study
the efficacy of topical sesame oil versus topical triamcinolone on oral lichen planus and salivary level of oxidative stress biomarker [mda]

Conditions: Oral Lichen Planus

Summary: use seseme oil and corticosteroid topically for two groups

* the enrolled patients will be divided randomly into two groups. * test group will receive topical sesame oil (3 times /day after eating) for a month. * control group will receive topical corticosteroid (3 times /day after eating) for a month. * assessment of the appearance score and severity of pain as well as the clinical parameter outcome will be done at baseline and at the end of two and four weeks and will be recorded in the patients' questionnaires \& by clinical sign score . mda will be measured at the baseline \& at the end of four weeks after treatment.

Eligibility criteria:
inclusion criteria: * patients who will be clinically diagnosed as having atrophic \&/or erosive oral lichen planus. * patients with no history of taking topical corticosteroids for the last 2 months and systemic corticosteroid for the last 6 months * patients who agree to take medication and follow up . exclusion criteria: * pregnant and lactating ladies. * patients with history of topical steroids during last 2 months \& systemic steroids during last 6 months. * patients with recent dental filling associated with the lesion or associated with recent drug administration. * patient with history of diabetes or hypertension or those with positive hcv ab or hbs ag.

Keywords: oral lichen planus sesame oil corticosteroid mda
comparison between hegab splint, arthrocentesis, and arthroscopy in treatment of tmj closed lock

Conditions: TMJ Disorder; TMJ Disc Disorder

Summary: this prospective, randomized control study aimed to compare the clinical outcome of hegab splint, arthrocentesis, and arthroscopy in treatment of tmj closed lock. the study sample was derived from the population of patients who presented for evaluation and treatment of tmj disorders.

this prospective, randomized control study aimed to compare the clinical outcome of hegab splint, arthrocentesis, and arthroscopy in treatment of tmj closed lock. the study sample was derived from the population of patients who presented for evaluation and treatment of tmj disorders. the patients were randomly assigned to one of the following three groups: group i (control): patients treated by hegab splint. group ii: patients treated by arthrocentesis with injection of ha/prp mix plus hegab splint. group iii: arthroscopy with injection of ha/prp mix plus hegab splint. the primary outcome variable was the change in pain using a visual analog scale, and improvement of maximum voluntary mouth opening. the secondary outcome variable was the change in joint sound. the third category of variables (age and sex) was evaluated in relation to the outcomes.

Eligibility criteria:
inclusion criteria: * patients with tmj closed lock confirmed exclusion criteria: * rheumatoid arthritis psoriatic arthritis juvenile arthritis those receiving anticoagulant therapy
effect of weight & insulin sensitivity on reproductive function in pcos: studies in skeletal muscle & adipose

Conditions: Polycystic Ovary Syndrome

Summary: the overall objective of this ancillary study is to obtain skeletal muscle and subcutaneous adipose tissue biopsies from women with polycystic ovary syndrome enrolled in the pulse study (nct01482286).

muscle and adipose tissues will be appropriately collected and banked for future studies such as to measure expression of candidate genes involved with carbohydrate and fat oxidation and mitochondrial function by rt-pcr, protein content by western blot, enzyme activity by enzymatic assays and to perform functional studies under varying conditions (for example before and after treatment with insulin, testosterone, serum) to quantify insulin signaling and carbohydrate and fat oxidation in primary human cultures.

Eligibility criteria:
inclusion criteria: * enrolled in pulse nct01482286 exclusion criteria: * withdraw from pulse nct01482286

Keywords: pcos, weight, insulin sensitivity, reproductive function
topical corticosteroid use in addition to oral antivirals for prevention of recurrence of herpes simplex virus (hsv) keratitis

Conditions: Herpes Simplex Virus Keratitis

Summary: this is a prospective, randomized clinical trial looking to determine the role of prophylactic treatment with topical corticosteroids in preventing recurrences in patients with a history of infectious epithelial keratitis, stromal keratitis,endotheliitis, or iridocyclitis. patients will be enrolled to one of two treatment arms: control arm: oral acyclovir 400 mg bid or valacyclovir 500 mg daily or study arm: oral acyclovir 400 mg bid or valacyclovir 500 mg qdaily + topical corticosteroid eye drops.


Eligibility criteria:
inclusion criteria: * subject capable of giving informed consent and if not, an acceptable surrogate capable of giving informed consent on behalf of the subject. * diagnosed with a history of herpetic eye disease * three or more episodes of hsv keratitis based on medical record documentation of episodes with infectious epithelial keratitis, immune stromal keratitis with or without epithelial ulceration, endothelitis, or iridocyclitis. * prior history of hsv keratitis based on medical record documentation of episode of infectious epithelial keratitis, immune stromal keratitis with or without epithelial ulceration, endothelitis, or iridocyclitis and corneal scarring in the central 4mm zone. exclusion criteria: * persons who are pregnant or nursing or intend to become pregnant or nurse in the next one year. * allergy to acyclovir, fluoromethalone, loteprednol, prednisolone acetate, prednisolone sodium phosphate, or any components of the formulations. * persons who are incarcerated. * unable to give informed consent or have an acceptable surrogate capable of giving informed consent on behalf of the subject. * persons with systemic medical problems who do not agree to have continued medical follow-up. * history of topical corticosteroids to the eyelids or ocular surface of the involved eye within the prior 30 days prior to enrollment. * patients with 3 or more episodes of uveitis in the past 12 months. * history of keratoplasy or keratorefractive surgery of the involved eye. * history of open or closed angle glaucoma or ocular hypertension on gtts. * history of systemic steroid use within the prior 30 days. * unable to comply with the study protocol or in the opinion of the investigator would not be a candidate for participation. * persons who are unable to instill gtts despite training/caregiver.
effect of feedback and practice on probabilistic decision making in attention deficit and hyperactivity disorder

Conditions: ADHD

Summary: the purpose of this study is to determine how feedback and practice affect decision making in adolescents with attention deficit and hyperactivity disorder. participants will have to choose between low and certain outcome and a higher but uncertain outcome, with or without serial feedback after each trial. participants will perform the task twice to examine practice effects.


Eligibility criteria:
inclusion criteria: * adhd exclusion criteria: * current major depression, * psychosis, * autism, * tourette syndrome

Keywords: adhd probabilistic choice feedback practice
imaging biomarkers to validate response in enzalutamide-treated mcrpc

Conditions: Prostatic Neoplasms

Summary: to determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by naf pet/ct, in patients with metastatic castrate-resistant prostate cancer.


Eligibility criteria:
inclusion criteria: * histologically proven adenocarcinoma of the prostate. * identifiable prostate cancer-related osseous metastases on bone scan or naf pet/ct in the vertebral body, pelvis or other bone. such lesions must be amenable to serial naf pet/ct imaging. preference will be given to subjects with multiple lesions that can be imaged in one image acquisition session to obtain maximal information as well as locations of lesions amenable to bone biopsies. * patients must be starting enzalutamide for treatment of metastatic castrate-resistant prostate, with cycle 1 day 1 occurring within 14 days after the first baseline naf pet/ct. subjects will be allowed to receive enzalutamide treatment on a concurrent study as long as the enzalutamide treatment study does not prohibit concurrent participation. * men of all races and ethnic groups of age ≥18 years. * the effects of naf on the developing human fetus are unknown. for this reason and because radiopharmaceuticals used for diagnostic imaging and other therapeutic agents and imaging procedures used in this trial may be or are known to be teratogenic, men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. * patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging and undergo bone biopsies. * patients must have both the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * known bleeding diathesis or on therapeutic anticoagulants (warfarin, low-molecular heparin, heparin analogues) that would increase risk of complications from bone biopsies. * history of allergic reactions attributed to compounds of similar chemical or biologic composition to sodium fluoride f-18 (naf).
vascular changes in pre-eclamptic patients and its impact on pregnancy outcome.

Conditions: Pre-Eclampsia

Summary: normal pregnancy is associated with vasodilation and decreased peripheral resistance, which is detected as early as 5 weeks' gestation . pre-eclampsia is a multi-system disorder of the second half of pregnancy , which is characterized by increased vascular reactivity and peripheral resistance with pathological changes that are consistent with impaired blood flow to the affected vascular beds. investigators will evaluate fetal and maternal vascular changes in normotensive and pre-eclamptic patients by ultrasound and doppler and their impact on prediction of pregnancy outcome.

pre-eclampsia affects 2-8% of all pregnancies, although treatment is generally effective. however, 10-15% of direct maternal deaths are associated with pre-eclampsia and eclampsia(who, 2011). there is a considerable evidence that generalized endothelial dysfunction underlies the clinical manifestations of the disease (oladipupo et al., 2014). it has been demonstrated that peripheral nutritive blood flow is impaired in pregnancies complicated by pre-eclampsia and precedes onset of the disorder (kenny et al., 2014). the pathophysiological mechanism is characterized by a failure of the trophoblastic invasion of the spiral arteries which may be associated with an increased vascular resistance of the uterine artery and a decreased perfusion of placenta. (al-jameil et al ; 2014 ) ultrasound of the brachial artery, and doppler ultrasound of the carotid artery and uterine artery are propaedeutic , non-invasive methods that contribute to the understanding of the pathophysiology of pe and eclampsia (takata et al., 2002 ). doppler assessment of the placental circulation plays an important role in screening for impaired placentation and its complications of preeclampsia, intrauterine growth restriction and perinatal death. assessment of the fetal circulation is essential in the better understanding of the pathophysiology of a wide range of pathological pregnancies and their clinical management(ghidini \& vergani, 2012).

Eligibility criteria:
inclusion criteria: 1. all women will be : * nonsmokers, * nondiabetic, * with no family history of vascular diseases. 2. gestational age at enrolment \>28 and \<34 weeks of gestation. 3. singleton pregnancy. 4. informed consent. 5. 50 normotensive pregnant women without complications will be defined as controls. 6. 50 pre-eclamptic patients. exclusion criteria: * 1. patients who presented to labor and delivery were excluded as subjects. 2. growth-restricted fetus due to: * marginal insertion of the umbilical cord, * placental infarction, * fetal minor heart anomaly, * fetal viral infection. 3. refusal of patient to participate in the study. 4. multiple gestations. 5. autoimmune diseases 6. previous history of pe or iugr.